TNK2 and neoplasm: Although vehicle-treated mice formed robust CRPC tumors, tumor growth was compromised in (R)-9b, SHP099, and Enzalutamide treated mice, with the smallest tumors in ACK1 and SHP2 inhibitor-treated mice (Fig. 7a–c).